RecruitingPhase 2NCT05050929
RAPid SimPLE Targeted Radiation Treatment for Brain Metastases
Randomized Phase II Non-Inferiority Study of 5-Day Versus 1-Day RAPid SimPLE (RAPPLE) Targeted Radiation Treatment for Brain Metastases
Sponsor
British Columbia Cancer Agency
Enrollment
100 participants
Start Date
Jul 1, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
The aim of the study is to show that rapid, simple targeted radiotherapy to brain metastases with 8 Gy / 1 is non-inferior to 20 Gy / 5 in terms of overall survival for patients with poor prognosis.
Eligibility
Min Age: 18 YearsMax Age: 100 Years
Inclusion Criteria11
- Subjects must meet all of the following criteria to be eligible for participation in this study:
- Age ≥ 18
- Pathological diagnosis of a non-hematopoietic malignancy
- Brain metastases of any size
- Any number of untreated or progressing, previously treated brain metastases that can all be contoured and targeted
- Presence of extracranial disease
- Diagnosis-Specific Graded Prognostic Assessment ≤ 2.0. (https://brainmetgpa.com/) or Graded Prognostic Assessment ≤ 2.0 (Appendix I)
- Able to complete the EuroQOL (EQ-5D-5L) questionnaire
- Willing and able to have regular imaging follow up
- Feasible to start protocol treatment within 14 days of participant enrolment
- Karnofsky Performance Score (KPS) ≥ 50
Exclusion Criteria12
- Subjects are excluded from the study if any of the following criteria apply:
- Inability to have a brain MRI
- WBRT less than 3 months prior to randomization
- Disseminated leptomeningeal carcinomatosis (limited pachymeningeal disease is permitted)
- Multiple sclerosis
- Neurologically declining despite corticosteroids
- Appropriate for surgery or stereotactic radiosurgery
- Germ cell and primary brain tumours
- Systemic lupus erythematosis, scleroderma, or other connective tissue disorders not in remission
- Any other serious intercurrent illness or medical condition judged by the local investigator to compromise the participant's safety, preclude safe administration of the planned protocol treatment, or prevent the participant from being managed according to the protocol guidelines
- Pregnancy
- Potentially fertile men or women of childbearing potential who are unwilling to employ highly effective contraception
Interventions
RADIATIONTargeting All Brain Metastases
Volumetric Modulated Arc Therapy
Locations(6)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05050929
Related Trials
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
NCT055598531 location
Brain Imaging Biomarkers in Patients With Brain Metastasis
NCT041972971 location
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
NCT057895891 location
Trial of Preoperative Radiosurgery Versus Postoperative Stereotactic Radiotherapy for Resectable Brain Metastases
NCT0512423610 locations
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
NCT060473796 locations